8-K: Predictive Oncology Reports Q2 2025 Results Amid Strategic Shift

Predictive Oncology reported a reduced net loss and cash burn in Q2 2025, alongside a significant revenue decline, as it prepares for a major ChemoFx market expansion and secures new funding.

Summary

• Predictive Oncology reported a loss from continuing operations of approximately $2.0 million for the quarter ended June 30, 2025, an improvement from $2.46 million in the prior year.
• Basic and diluted loss per common share from continuing operations improved to $0.22 for Q2 2025, compared to $0.53 for Q2 2024.
• Revenue for Q2 2025 was $2,682, a substantial decrease from $67,255 in Q2 2024, primarily due to decreased sales of tumor-specific 3D models and 3D kits.
• Net cash used in operating activities of continuing operations decreased to $4,280,632 for the six months ended June 30, 2025, from $5,504,158 in the comparable 2024 period.
• The company concluded Q2 2025 with $506,078 in cash and cash equivalents, down from $611,822 as of December 31, 2024.
• Stockholders deficit increased significantly to $1,653,400 as of June 30, 2025, from $202,610 as of December 31, 2024.
• Preparations are advancing for an aggressive market expansion of ChemoFx in the U.S. and a de novo launch in Europe, anticipated in Q4 2025, focusing initially on ovarian and gynecological cancers.
• Successfully developed two distinct 3D liver toxicity models (human and rat) exclusively for Labcorp.
• Identified promising drug candidates for repurposing, including Afuresertib (breast), Alisertib (colon), and Entinosta (colon), from publicly available datasets of abandoned drugs.
• Secured a standby equity purchase agreement for up to $10 million with YA II PN, LTD, an investment fund managed by Yorkville Advisors Global, LP.
• Raised approximately $586,000 in combined gross proceeds during Q2 2025 through a private placement and its At-the-Market (ATM) facility.

Sentiment

Score: 4

Explanation: The sentiment is mixed to slightly negative. While the company showed improved loss figures and cash burn, and announced significant strategic initiatives and a new funding facility, the drastic decline in revenue and the worsening stockholders' deficit are significant concerns. The operational progress is promising for the future, but current financial performance is weak.

Positives

• Loss from continuing operations decreased to $2.0 million in Q2 2025 from $2.46 million in Q2 2024, indicating improved profitability metrics.
• Basic and diluted loss per common share from continuing operations improved to $0.22 in Q2 2025 from $0.53 in Q2 2024.
• Net cash used in operating activities of continuing operations decreased by over $1.2 million for the six months ended June 30, 2025, compared to the prior year, reflecting lower cash operating losses.
• Successfully developed two distinct 3D liver toxicity models for Labcorp, a global leader in laboratory services, demonstrating scientific progress and potential for future collaborations.
• Advanced preparations for an aggressive market expansion of ChemoFx in the U.S. and a de novo launch in Europe, anticipated in Q4 2025, which represents significant potential future revenue.
• Identified and are exploring promising drug candidates for repurposing (Afuresertib, Alisertib, Entinosta) using AI/ML on publicly available datasets, potentially opening new revenue streams.
• Secured a standby equity purchase agreement for up to $10 million with Yorkville Advisors, providing a flexible source of capital for strategic initiatives.

Negatives

• Revenue for Q2 2025 was $2,682, a significant decrease of approximately 96% from $67,255 in Q2 2024, primarily due to decreased sales of tumor-specific 3D models and 3D kits.
• The company's cash and cash equivalents decreased to $506,078 as of June 30, 2025, from $611,822 as of December 31, 2024.
• Stockholders deficit significantly increased to $1,653,400 as of June 30, 2025, from $202,610 as of December 31, 2024, indicating a worsening equity position.
• Sales and marketing expenses increased by over 100% to $268,959 in Q2 2025 compared to $134,186 in Q2 2024, driven by increased digital marketing consultant fees.

Risks

• Risks related to the success of collaboration arrangements, commercialization activities, and product sales levels by collaboration partners.
• Other factors discussed under the heading Risk Factors in the company's filings with the SEC.

Future Outlook

The company anticipates generating meaningful revenues in 2026 and beyond, driven by the expansion of its ChemoFx live-cell tumor profiling assay in the U.S. and a de novo launch in Europe, both expected in Q4 2025. They also plan to expand their drug repurposing approach to evaluate additional abandoned drugs.

Management Comments

• "meaningful steps toward strengthening our financial position while also creating a foundation from which to generate meaningful revenues in 2026 and beyond."
• "remain acutely focused on our core AI-driven drug and biomarker discovery and drug repurposing initiatives, we are also working tirelessly to expand availability of our proprietary ChemoFx live-cell tumor profiling assay in the U.S. while preparing for a de novo launch in Europe, both anticipated in Q4 of this year."
• "ChemoFx not only represents significant potential revenue for our Company, but it is also the primary assay by which we populated our vast biobank of more than 150,000 patient tumor samples, which we regard as a key differentiator."
• "the share purchase agreement that we announced just a few weeks ago with Yorkville Advisors represents an efficient and flexible source of capital that we can utilize to advance these initiatives. We are grateful to the Yorkville team for their support of our company and our vision, and we look forward to a long and mutually beneficial partnership."

Industry Context

Predictive Oncology operates in the rapidly evolving oncology drug discovery and development sector, leveraging AI and machine learning to accelerate processes. The focus on live-cell drug response assays (ChemoFx) and drug repurposing aligns with industry trends towards personalized medicine and efficient drug development, particularly for difficult-to-treat cancers like ovarian cancer. The collaboration with Labcorp for 3D liver toxicity models also highlights engagement with key players in the broader pharmaceutical services industry.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks.

Stakeholder Impact

• Shareholders: Potential for dilution due to the standby equity purchase agreement and ATM facility, but also potential for long-term value creation if ChemoFx expansion and drug repurposing initiatives succeed.
• Employees: Decreased headcount noted in financial statements, indicating potential workforce adjustments.
• Customers: Continued development of ChemoFx and new 3D models for Labcorp could benefit future customers seeking advanced oncology and toxicity testing solutions.
• Creditors: The increased stockholders deficit and reliance on equity financing may impact creditworthiness, though the new capital facility provides some liquidity.

Next Steps

• Aggressive market expansion of ChemoFx in the U.S. in Q4 2025.
• De novo launch of ChemoFx in Europe in Q4 2025.
• Further exploration of identified drug candidates (Afuresertib, Alisertib, Entinosta) for new colon and breast tumor indications.
• Expanding the drug repurposing approach to evaluate additional abandoned drugs using publicly available datasets.
• Generating meaningful revenues in 2026 and beyond.

Key Dates

Recommendation

While the company demonstrated improved loss metrics and secured a significant financing facility, the drastic 96% decline in revenue for the quarter is a major concern, indicating a contraction in current business operations. The strategic focus on ChemoFx expansion and drug repurposing offers long-term potential, but these initiatives are still in early stages of commercialization, with meaningful revenues not expected until 2026. Given the high-risk profile, significant cash burn, and the need for substantial future revenue growth to justify current valuation, a 'hold' recommendation is appropriate. Investors should await clearer signs of successful ChemoFx commercialization and revenue generation before considering further investment.

Keywords

Oncology, Artificial Intelligence, Machine Learning, Drug Discovery, Drug Development, ChemoFx, Cancer Treatment, Biorepository, CLIA Laboratory, Biotechnology, Pharmaceuticals, Precision Medicine, Drug Repurposing, Ovarian Cancer, Gynecological Cancers, Liver Toxicity Models, Labcorp, SEC Filing, Financial Results